WntResearch announces that patient recruitment for initial safety assessment has been successfully achieved

An important milestone is reached as WntResearch enrolls the twentieth patient in the NeoFox trial; this means that the recruitment target for performing the initial safety assessment has been reached.

WntResearch's Phase 2 study has now enrolled patient number 20, and an initial safety assessment will be performed on these patients once they have completed treatment, which according to plan will be in February 2020 at the latest. The Company is now seeing a significantly improved patient recruitment following the measures that have been adopted in the clinics, resulting in 6 new patients during October (compared to 14 in total during the preceding six-month period). 

The application to include four additional clinics in Spain has been granted. One of these clinics has already been activated, and agreements have been signed or are close to being signed with the other three. An application to start three more clinics is awaiting a decision in the near future. WntResearch has also decided to close two clinics that have failed to live up to expectations, and is monitoring the development of other clinics in order to focus activities to those that are productive.  

WntResearch has decided to abort the continuation of the plans to initiate the study in the Netherlands, where only one clinic would be able to be activated in the near future. 

"We are pleased that the measures we have taken, and our active monitoring, have provided the results we wanted to see with regard to patient recruitment. We are continuing to pursue the study, actively and focused, in order to reach our highly ambitious goals," says Peter Morsing, CEO of WntResearch. 

For more information, please contact:

Peter Morsing, CEO, WntResearch AB
E-mail: pm@wntresearch.com

Telephone: +46 727 200711

This information is information that WntResearch is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on November 4, 2019.

About WntResearch 

WntResearch is developing an entirely new kind of cancer drug, which inhibits the tumour cells’ ability to spread through the body and metastasize. The majority of cancer deaths are due to metastases, and there are no therapies available that can prevent that. Foxy-5, the Company's most advanced drug candidate, is a peptide that mimics the body's own WNT5A protein. In preclinical trials, Foxy-5 has demonstrated ability to suppress the mobility and invasive power of cancer cells, and thus to inhibit metastasis. Phase 1 studies on patients with colon, prostate and breast cancer have demonstrated a good safety profile and favourable pharmacokinetics, and early data indicates biological activity. A Phase 2 multicenter study was recently initiated on patients with colon cancer, in order to study the anti-metastasizing efficacy of Foxy-5. WntResearch’s share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com 



wkr0006.pdf